Clincosm LogoSign in Get a demo

Pattern of Statins Use in Catalonia

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT01477944
Collaborator
(none)
180,723
Enrollment

Study Details

Study Description

Brief Summary

To describe the new statins prescription pattern in Catalonia (getting their first prescription for any statin, or receiving a change in their statin treatment including switching, changing in doses or adding ezetimibe/fibrates) since September 2009.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Pattern of statins use in Catalonia.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    180723 participants
    Time Perspective:
    Retrospective
    Official Title:
    Pattern of Statins Use in Catalonia
    Study Start Date :
    Feb 1, 2012
    Actual Primary Completion Date :
    Feb 1, 2012
    Actual Study Completion Date :
    Feb 1, 2012

    Outcome Measures

    Primary Outcome Measures

    1. Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches and add-on therapy, in patients with hypercholesterolemia and on treatment with statins from the index date. [From 1st September 2009 to 30th August 2010]

    2. Type of prescriber [From 1st September 2009 to 30th August 2010]

      Number of patient, whom the drug was prescribed by the specified type of prescriber (specialist, general practitioner, etc.)

    3. Date of change from previous statin to new. [From 1st September 2009 to 30th August 2010]

    Secondary Outcome Measures

    1. Description of demographic data including: Sex, Age, Height (cm), Weight (kg), Smoking habits (packs-years), Alcohol consume habits (units/week), active worker or retired, Pregnancy. [From 1st September 2009 to 30th August 2010]

    2. Total cholesterol [From 1st September 2009 to 30th August 2010]

      Total Cholesterol data was collected till the last laboratory values before the date of change from previous statin to new statin. That values will be collected for all the patients fulfilling criteria.

    3. Low Density Lipoprotein (LDL) cholesterol concentration [From 1st September 2009 to 30th August 2010]

      LDL cholesterol data was collected till the last laboratory values before the date of change from previous statin to new statin.

    4. High Density Lipoproteins (HDL) cholesterol concentration [From 1st September 2009 to 30th August 2010]

      HDL data was collected till the last laboratory values before the date of change from previous statin to new statin.

    5. Triglicerides (TG) concentration [From 1st September 2009 to 30th August 2010]

      TG data was collected till the last laboratory values before the date of change from previous statin to new statin.

    6. Aspartate Aminotransferase (ASAT) concentration [From 1st September 2009 to 30th August 2010]

      ASAT data was collected till the last laboratory values before the date of change from previous statin to new statin.

    7. Serum Glucose concentration [From 1st September 2009 to 30th August 2010]

      Serum Glucose data was collected till the last laboratory values before the date of change from previous statin to new statin.

    8. Serum Creatin Kinase (CK) concentration [From 1st September 2009 to 30th August 2010]

      CK data was collected till the last laboratory values before the date of change from previous statin to new statin.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    • Patient with a new prescription of statin Patients receiving one or more changes of the statins treatment

    Exclusion Criteria

    • Patient with not full information

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AstraZeneca
    ClinicalTrials.gov Identifier:
    NCT01477944
    Other Study ID Numbers:
    • NIS-CES-CRE-2011/1
    First Posted:
    Nov 23, 2011
    Last Update Posted:
    Feb 22, 2012
    Last Verified:
    Feb 1, 2012
    Keywords provided by AstraZeneca
    Statins pattern of use
    Hypercholesterolemic patients
    Statins
    Additional relevant MeSH terms:
    Hypercholesterolemia

    Study Results

    No Results Posted as of Feb 22, 2012